Lido Advisors
ADMA icon

Lido Advisors’s ADMA Biologics ADMA Stock Holding History

Lido Advisors’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$181K Buy
20,107
+3,000
+18% +$47.3K ﹤0.01% 1791
2025
Q4 		$263K Buy
17,107
+629
+4% +$10.6K ﹤0.01% 1635
2025
Q3 		$242K Buy
16,478
+1,599
+11% +$27.4K ﹤0.01% 1599
2025
Q2 		$271K Buy
+14,879
New +$303K ﹤0.01% 1383

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Lido Advisors's ADMA Position: Q1 2026 in Review

Lido Advisors increased its ADMA Biologics (ADMA) stake by 18% in Q1 2026, buying an estimated $47.3K and bringing the position to 20,107 shares worth $181K. The position accounts for ﹤0.01% of the portfolio, ranked #1791.

Lido Advisors first reported a position in ADMA in Q2 2025 and has held it in 4 quarters since. The position peaked at $271K in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Lido Advisors held 20,107 shares of ADMA Biologics worth $181K as of Q1 2026.
  • Lido Advisors bought 3,000 ADMA Biologics shares in Q1 2026, an estimated $47.3K.
  • ADMA Biologics made up ﹤0.01% of Lido Advisors's portfolio in Q1 2026, its #1791 holding.
  • Lido Advisors first reported a position in ADMA Biologics in Q2 2025 and has held it in 4 quarters since.
  • Lido Advisors's ADMA Biologics position peaked at $271K in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Lido Advisors's 13F filing for Q1 2026, filed 13 May 2026.